Revisión por temas de las últimas publicaciones en las que han participado miembros de GETECCU

Archivado en Noticias

EPIDEMIOLOGÍA

1. Extraintestinal Manifestations in Patients with Inflammatory Bowel Disease: Study Based on the ENEIDA Registry
Algaba A., Guerra I., Ricart E, et al. [published online ahead of print, 2020 Jul 15]. Dig Dis Sci. 2020;10.1007/s10620-020-06424-x. doi:10.1007/s10620-020-06424-x

2. Impact of immune-mediated diseases in inflammatory bowel disease and implications in therapeutic approach.
García M.J., Pascual M., Del Pozo C., et al. Sci Rep. 2020;10(1):10731. Published 2020 Jul 1. doi:10.1038/s41598-020-67710-2

3. Management of COVID-19 Pandemic in Spanish Inflammatory Bowel Disease Units: Results From a National Survey.
Martin Arranz E., Suarez Ferrer C., García Ramírez L., et al. Inflamm Bowel Dis. 2020;26(8):1149-1154. doi:10.1093/ibd/izaa142

4. 2019 novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases.
Taxonera C., Sagastagoitia I., Alba C., Mañas N., Olivares D, Rey E. Aliment Pharmacol Ther. 2020;52(2):276-283. doi:10.1111/apt.15804

5. Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents
Guasch M., Cañete F., Ordás I., et al. [published online ahead of print, 2020 Apr 29]. J Gastroenterol Hepatol. 2020;10.1111/jgh.15084. doi:10.1111/jgh.15084

6. Idiopathic acute pancreatitis in patients with inflammatory bowel disease: A multicenter cohort study.
García García de Paredes A., Rodríguez de Santiago E., Rodríguez-Escaja C., et al. Pancreatology. 2020;20(3):331-337. doi:10.1016/j.pan.2020.02.007

7. Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study.
Burisch J., Vardi H., Schwartz D., et al. Lancet Gastroenterol Hepatol. 2020;5(5):454-464. doi:10.1016/S2468-1253(20)30012-1

8. Diagnosis and Outcome of Oesophageal Crohn’s Disease.
Vale Rodrigues R., Sladek M., Katsanos K., et al. J Crohns Colitis. 2020;14(5):624-629. doi:10.1093/ecco-jcc/jjz201

9. Interstitial and Granulomatous Lung Disease in Inflammatory Bowel Disease Patients.
Eliadou E., Moleiro J., Ribaldone D.G., et al. J Crohns Colitis. 2020;14(4):480-489. doi:10.1093/ecco-jcc/jjz165

10. Metabolic bone disease in patients diagnosed with inflammatory bowel disease from Spain.
Miranda-Bautista J., Verdejo C., Díaz-Redondo A., et al. Therap Adv Gastroenterol. 2019;12:1756284819862152. Published 2019 Jul 31. doi:10.1177/1756284819862152

11. A Global, Prospective, Observational Study Measuring Disease Burden and Suffering in Patients with Ulcerative Colitis Using the Pictorial Representation of Illness and Self-Measure Tool
Ghosh S., Sensky T., Casellas F., et al. [published online ahead of print, 2020 Jul 29]. J Crohns Colitis. 2020;jjaa159. doi:10.1093/ecco-jcc/jjaa159

archivado en Noticias | publicado el 14 de septiembre de 2020 | última actualización: 15 de septiembre de 2020 10:01
Formación EII
Canal de GETECCU en YouTube
Base de datos ENEIDA
VIDEOS DESTACADOS

puedes ver todos los vídeos en nuestros canales de video GETECCU en YouTube y G-EducaEII en YouTube

PODCASTS GETECCU

Escucha todos nuestros podcasts GETECCU Podcasts

Nuestros patrocinadores|lea nuestra política de patrocinio
ABBVIE
GILEAD
JANSSEN
MSD
PFIZER
TAKEDA
ADACYTE
AMGEN
DR. FALK
FERRING
KERN PHARMA
ROCHE
BIOGEN
BMS
CHIESI
FAES FARMA
FRESENIUS KABI
SANDOZ
TILLOTTS PHARMA